1-4 of 4
Michael Dickinson, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study

Alice McDonald, Elizabeth Thomas, Scott Daigle, Franck Morschhauser, Gilles Salles, MD PhD, Vincent Ribrag, Pamela McKay, MD, Herve Tilly, MD, Anna Schmitt, Connie Lee Batlevi, MD, Christophe Fruchart, Peter Johnson, MD, Michael Dickinson, MD, Stephen Opat, Wojciech Jurczak, Guillaume Cartron, Thierry Lamy, Pier Luigi Zinzani, MD, Sarit Assouline, John Radford, MD FRCP, John G. Gribben, Corinne Haioun, MD, Aristeidis Chaidos, MD PhD, Steven Le Gouill, MD PhD, Alicia Clawson, John Larus, Stephen J Blakemore
Journal: Blood
Blood (2018) 132 (Supplement 1): 4097.
https://doi.org/10.1182/blood-2018-99-115132
Published: 2018
Journal Articles

Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Vincent Ribrag, Franck Morschhauser, Pamela McKay, MD, Gilles Andre Salles, Connie Lee Batlevi, MD, Anna Schmitt, Herve Tilly, MD, Guillaume Cartron, Catherine Thieblemont, MD, Christophe Fruchart, John G. Gribben, Thierry Lamy, Steven Le Gouill, Reda Bouabdallah, MD, Michael Dickinson, MD, Stephen Opat, Deyaa Adib, Stephen J Blakemore, John Larus, Peter Johnson, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4196.
https://doi.org/10.1182/blood-2018-99-113411
Published: 2018
Journal Articles

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Franck Morschhauser, MD, Fritz Offner, MD, Anna Sureda, MD, Gilles Andre Salles, MD PhD, Carmelo Carlo-Stella, MD, Joaquin Martinez Lopez, MD, Denise Thomas, BS, Peter N Morcos, PhD, Betsy Quackenbush, MD, Cristiano Ferlini, MD, Marina Bacac, PhD, Ann-Marie E. Broeske, PhD, Natalie Dimier, PhD, Tom Moore, MD, Martin Weisser, MD, Michael Dickinson, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 226.
https://doi.org/10.1182/blood-2018-99-110207
Published: 2018
Journal Articles

A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)

Michael Dickinson, MD, Manali Kamdar, MD, Brian J.P Huntly, Carlos Fernández De Larrea, MD PhD, Raul Cordoba, MD PhD, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Won-Seog Kim, MD PhD, Jin Seok Kim, MD PhD, Mark Dawson, MD PhD, Paul Sung-Hao Yeh, MBBS, FRCPA, FRACP, Faisal Basheer, MBBChir, MA, Paolo Gallipoli, PhD, Aristeidis Chaidos, MD PhD, Alejandro Martín, MD, Thierry Horner, PhD, James Winnberg, MS, Lijoy K Mathew, PhD, Jeffrey Botbyl, MS, Natalie Karpinich, PhD, Brandon E. Kremer, MD PhD, Arindam Dhar, MBBS,MDPhD, Anastasios Karadimitris, FRCPath, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1682.
https://doi.org/10.1182/blood-2018-99-117089
Published: 2018